Drug May Extend Life When Breast Cancer Spreads

... -- A new study affirms that the chemotherapy drug abraxane is more effective, with less troublesome side effe...tic breast cancer. When compared with Taxotere, abraxane extended the time before a recurrence by almost se...een presented at national meetings, reaffirms that abraxane is a very active drug, is well-tolerated and appea...

NYU Langone Medical Center's tip sheet to the 44th annual meeting of ASCO

...the feasibility and efficacy of the triple combination of oblimersen (OBL), abraxane (ABX), and temozolomide (TMZ) in metastatic melanoma and normal LDH NYU C...with metastatic melanoma received a therapy that combined oblimersen (OBL), abraxane (ABX) and temozolomide (TMZ). All 14 enrolled patients belonging to the fir...

Study looks at new bladder cancer therapy for patients unresponsive to standard treatment

...nter are investigating an FDA-approved metastatic breast-cancer drug called abraxane that may prove a safe and effective alternative to surgery for these patien...inistration at higher concentrations," says Dr. McKiernan. "In one study of abraxane for metastatic breast cancer, the drug successfully shrank tumors and had f...

Abraxane in Medical Technology

Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology

...92 Saturday, May 31, 2008. -- A Phase I/II Study to Determine the Feasibility and Efficacy of the Triple Combination of Oblimersen (OBL), abraxane (ABX), and Temozolomide (TMZ) in Metastatic Melanoma and Normal LDH. Poster # 16 Abstract No: 9027 Sunday, June 1, 2008. -- Effect of the...

Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress

...naive patients with advanced melanoma and low LDH. Presenter: A. Bedikian. A Phase I study of the triple combination of oblimersen, temozolomide, and abraxane in patients with advanced melanoma and normal LDH. Presenter: A. Pavlick. Pharmacokinetics of oblimersen in combination with dacarbazine in metastati...

Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response

...d. The most serious adverse events associated with abraxane in the randomized metastatic breast cancer study f... for ABRAXANE(R), please visit www.abraxane.com. abraxane was developed by Abraxis BioScience, Inc. abraxane is marketed in the United States under a co-promot...

Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway

...G HSP90 inhibitor (ABI 010), among others. About abraxane (R) The U.S. Food and Drug Administration approved abraxane (R) for Injectable Suspension (paclitaxel protein-...d. The most serious adverse events associated with abraxane in the randomized metastatic breast cancer study f...

Abraxane in Biological News

2 new therapies show promise for cancer patients

... The fact that we saw this kind of activity in a phase I trial is dramatic, Von Hoff said. The rationale behind the combination of Gemcitabine plus abraxane was based on careful science and was designed and executed by some of the leading experts in pancreas cancer in the world. While the data is prelimina...

Nanoparticle Breast Cancer Drug Approved by FDA

...t role in Food and Drug Administration approval of abraxane (paclitaxel protein-bound particles for injectable...the more common treatments showed improvement with abraxane and experienced less-severe side effects that made treatment more tolerable," Gradishar said. abraxane is engineered using a proprietary process (protein...

Abraxane in Biological Technology

Midwest large cap life science group strengthening in the third quarter

...l listing price on the NYSE. American Pharmaceutical Partners has also been on a roll ever since new CEO Al Heller took charge and its new cancer drug abraxane was approved by the FDA and has launched. A number of companies continued to suffer during the year including Abbott and Eli Lilly. Abbott was se...